Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Change in Cash (2019 - 2025)

Biodesix (BDSX) has disclosed Change in Cash for 7 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash rose 146.17% year-over-year to $2.4 million, compared with a TTM value of -$7.3 million through Dec 2025, down 18507.69%, and an annual FY2025 reading of -$7.3 million, down 18507.69% over the prior year.
  • Change in Cash was $2.4 million for Q4 2025 at Biodesix, up from -$4.1 million in the prior quarter.
  • Across five years, Change in Cash topped out at $30.7 million in Q2 2024 and bottomed at -$17.8 million in Q1 2023.
  • Average Change in Cash over 5 years is -$2.2 million, with a median of -$6.0 million recorded in 2021.
  • The sharpest move saw Change in Cash crashed 562.17% in 2021, then surged 1092.06% in 2022.
  • Year by year, Change in Cash stood at -$15.2 million in 2021, then surged by 283.63% to $27.9 million in 2022, then tumbled by 76.91% to $6.4 million in 2023, then crashed by 180.09% to -$5.2 million in 2024, then skyrocketed by 146.17% to $2.4 million in 2025.
  • Business Quant data shows Change in Cash for BDSX at $2.4 million in Q4 2025, -$4.1 million in Q3 2025, and $3.1 million in Q2 2025.